Kelly Nugent
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kelly Nugent has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Amy L. Pasternak
Department of Pharmacy Michigan Medicine Ann Arbor Michigan USA
4 shared publications - Daniel Louis Hertz
Department of Clinical Pharmacy University of Michigan College of Pharmacy Ann Arbor Michigan USA
4 shared publications - Faisal Shakeel
Department of Pharmacy, Sarhad University of Science and Information Technology, Peshawar, Pakistan
4 shared publications - Jung Won Kwon
University of Michigan–Ann Arbor 2 Ann Arbor
4 shared publications - Kyoin Koo
University of Michigan–Ann Arbor 2 Ann Arbor
4 shared publications - Nam Nguyen-Hoang
University of Michigan–Ann Arbor 2 Ann Arbor
4 shared publications
Latest Publications
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Tables S2-S4 from Identification of Additional DPYD Polymorphisms That Increase the Risk of Severe Fluoropyrimidine Toxicity and Improve Predictive Accuracy when Combined with Previously Validated Variants
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Tables S2-S4 from Identification of Additional DPYD Polymorphisms That Increase the Risk of Severe Fluoropyrimidine Toxicity and Improve Predictive Accuracy when Combined with Previously Validated Variants
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table S1 from Identification of Additional DPYD Polymorphisms That Increase the Risk of Severe Fluoropyrimidine Toxicity and Improve Predictive Accuracy when Combined with Previously Validated Variants
Supplemental Table S1 from Identification of Additional DPYD Polymorphisms That Increase the Risk of Severe Fluoropyrimidine Toxicity and Improve Predictive Accuracy when Combined with Previously Validated Variants
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table S1 from Identification of Additional DPYD Polymorphisms That Increase the Risk of Severe Fluoropyrimidine Toxicity and Improve Predictive Accuracy when Combined with Previously Validated Variants
Supplemental Table S1 from Identification of Additional DPYD Polymorphisms That Increase the Risk of Severe Fluoropyrimidine Toxicity and Improve Predictive Accuracy when Combined with Previously Validated Variants
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Data from Identification of Additional DPYD Polymorphisms That Increase the Risk of Severe Fluoropyrimidine Toxicity and Improve Predictive Accuracy when Combined with Previously Validated Variants
Purpose:Fluoropyrimidine (FP) chemotherapy can cause life-threatening toxicity. Four DPYD polymorphisms (DPYD*2A, *13, p.Asp949Val, and HapB3) are most well established to increase FP toxicity risk. This study aimed to identify additional DPYD polymorphisms that increase FP severe toxicity. Experimental Design:Adult patients treated with standard doses of systemic FP (5-fluorouracil/capecitabine) for any tumor type with available genetic data were included. The primary toxicity endpoint was a composite of Common Terminology Criteria for Adverse Event grade ≥3 toxicity or treatment modification due to toxicity in the first two FP cycles. A literature-curated list of suspected deleterious unvalidated DPYD variants was classified as uncommon (minor allele frequency <0.01) or common. The genetic association with toxicity was analyzed via multivariable logistic regression. Results:Among 849 eligible patients, the composite toxicity endpoint occurred in 25%. Genetic data were available for five uncommon and six common suspected deleterious DPYD variants. In the primary analysis of 799 patients who did not carry a validated variant, carriers of an uncommon deleterious variant (1.1% of patients) had significantly higher risk of toxicity than noncarriers (67% vs. 24%; adjusted OR, 7.36; 95% confidence interval, 1.75–38.20; P = 0.009). None of the common deleterious variants were associated with toxicity. Toxicity prediction in the entire cohort (n = 849) was slightly improved by testing the uncommon and validated variants versus testing only the validated variants (positive predictive value: 44.1% vs. 40%). Conclusions:Five uncommon DPYD variants, in combination, increase FP toxicity risk and improve risk prediction. Testing these variants could identify more high-risk patients who should receive adjusted FP doses to prevent severe toxicity.See related commentary by Gaddy et al., p. 3109
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Identification of Additional DPYD Polymorphisms That Increase the Risk of Severe Fluoropyrimidine Toxicity and Improve Predictive Accuracy when Combined with Previously Validated Variants
Purpose:Fluoropyrimidine (FP) chemotherapy can cause life-threatening toxicity. Four DPYD polymorphisms (DPYD*2A, *13, p.Asp949Val, and HapB3) are most well established to increase FP toxicity risk. This study aimed to identify additional DPYD polymorphisms that increase FP severe toxicity. Experimental Design:Adult patients treated with standard doses of systemic FP (5-fluorouracil/capecitabine) for any tumor type with available genetic data were included. The primary toxicity endpoint was a composite of Common Terminology Criteria for Adverse Event grade ≥3 toxicity or treatment modification due to toxicity in the first two FP cycles. A literature-curated list of suspected deleterious unvalidated DPYD variants was classified as uncommon (minor allele frequency <0.01) or common. The genetic association with toxicity was analyzed via multivariable logistic regression. Results:Among 849 eligible patients, the composite toxicity endpoint occurred in 25%. Genetic data were available for five uncommon and six common suspected deleterious DPYD variants. In the primary analysis of 799 patients who did not carry a validated variant, carriers of an uncommon deleterious variant (1.1% of patients) had significantly higher risk of toxicity than noncarriers (67% vs. 24%; adjusted OR, 7.36; 95% confidence interval, 1.75–38.20; P = 0.009). None of the common deleterious variants were associated with toxicity. Toxicity prediction in the entire cohort (n = 849) was slightly improved by testing the uncommon and validated variants versus testing only the validated variants (positive predictive value: 44.1% vs. 40%). Conclusions:Five uncommon DPYD variants, in combination, increase FP toxicity risk and improve risk prediction. Testing these variants could identify more high-risk patients who should receive adjusted FP doses to prevent severe toxicity.See related commentary by Gaddy et al., p. 3109
- 27 February 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (15) , 3269-3276
Identification of additional DPYD polymorphisms that increase the risk of severe fluoropyrimidine toxicity and improved predictive accuracy when combined with previously validated variants
Purpose: Fluoropyrimidine (FP) chemotherapy can cause life-threatening toxicity. Four DPYD polymorphisms (DPYD*2A, *13, p.Asp949Val, HapB3) are well-established to increase FP toxicity risk. This study aimed to identify additional DPYD polymorphisms that increase FP toxicity. Experimental Design: Adult patients treated with standard doses of systemic FP (5-fluorouracil/capecitabine) for any cancer with available DPYD genetic data were included. The primary endpoint was a composite of CTCAE grade ≥3 toxicity or treatment modification due to toxicity in the first two FP cycles. A literature-curated list of suspected deleterious unvalidated DPYD variants was classified as uncommon (minor allele frequency <0.01) or common. The genetic association with toxicity was analyzed via multivariable logistic regression. Results: Among 849 eligible patients, the composite toxicity endpoint occurred in 25%. Genetic data were available for five uncommon and six common suspected deleterious DPYD variants. In the primary analysis of 799 patients who did not carry a validated variant, carriers of uncommon deleterious variants (1.1% of patients) had significantly higher toxicity risk than non-carriers (67% vs. 24%; adjusted OR 7.36; 95% CI 1.75–38.20; p = 0.009). None of the common deleterious variants were associated with toxicity. Toxicity prediction in the entire cohort (n = 849) was slightly improved by testing the uncommon and validated variants vs. testing only the validated variants (positive predictive value: 44.1% vs. 40.0%). Conclusions: Five uncommon DPYD variants, in combination, increase FP toxicity risk and improve risk prediction. Testing these variants could identify more high-risk patients who should receive adjusted FP doses to prevent severe toxicity.
- 27 February 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (15) , 3269-3276
Identification of additional DPYD polymorphisms that increase the risk of severe fluoropyrimidine toxicity and improved predictive accuracy when combined with previously validated variants
Purpose: Fluoropyrimidine (FP) chemotherapy can cause life-threatening toxicity. Four DPYD polymorphisms (DPYD*2A, *13, p.Asp949Val, HapB3) are well-established to increase FP toxicity risk. This study aimed to identify additional DPYD polymorphisms that increase FP toxicity. Experimental Design: Adult patients treated with standard doses of systemic FP (5-fluorouracil/capecitabine) for any cancer with available DPYD genetic data were included. The primary endpoint was a composite of CTCAE grade ≥3 toxicity or treatment modification due to toxicity in the first two FP cycles. A literature-curated list of suspected deleterious unvalidated DPYD variants was classified as uncommon (minor allele frequency <0.01) or common. The genetic association with toxicity was analyzed via multivariable logistic regression. Results: Among 849 eligible patients, the composite toxicity endpoint occurred in 25%. Genetic data were available for five uncommon and six common suspected deleterious DPYD variants. In the primary analysis of 799 patients who did not carry a validated variant, carriers of uncommon deleterious variants (1.1% of patients) had significantly higher toxicity risk than non-carriers (67% vs. 24%; adjusted OR 7.36; 95% CI 1.75–38.20; p = 0.009). None of the common deleterious variants were associated with toxicity. Toxicity prediction in the entire cohort (n = 849) was slightly improved by testing the uncommon and validated variants vs. testing only the validated variants (positive predictive value: 44.1% vs. 40.0%). Conclusions: Five uncommon DPYD variants, in combination, increase FP toxicity risk and improve risk prediction. Testing these variants could identify more high-risk patients who should receive adjusted FP doses to prevent severe toxicity.